Bio News
Otsuka’s IgA nephropathy treatment Voyxact (sibeprenlimab) stabilized patients’ kidney function at near-normal levels for 2 years. In the phase 3 trial, the annual rate of change in estimated glomerular filtration rate (eGFR) improved by 0.3, showing a clear difference from the placebo group’s 4.2 decline. Otsuka filed for full approval with the FDA and more than doubled its sales forecast for this year to ¥60 billion.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
